Category: Uncategorized

KUALA LUMPUR, Aug 2 (Bernama) — Hong Kong is the ideal destination for families looking for a vacation, from thrilling theme parks and vibrant art and cultural attractions, to family-friendly hospitality options with easy access to the city’s must-see attractions.

No family stay in Hong Kong would be complete without a visit to the city’s world-class theme parks which are Hong Kong Disneyland and Ocean Park.

Children are able to have water fun at Hong Kong Disneyland which runs until Sept 3 whereby they can get up close to their favourite Disney characters, while toy soldiers armed with water sprayers will get wet and wild, at the Pixar Water Play Street Party.

This year also marks the 100th anniversary of Disney. Families must not miss the largest celebration event in town at Wharf Malls, which will feature three unique themed journeys until Sept 3, according to a statement.

Meanwhile, families can splash into summer at Ocean Park, Hong Kong’s homegrown theme park with the return of one of the city’s favourite summer activities whereby the whole family may participate in an epic water gun battle, or enjoy a dreamy foam party, live music and photo opportunities until Aug 27.

Travellers can take a mesmerising creative journey at teamLab Future Park Hong Kong, a new immersive experience by world-famous art collectives teamLab, bringing art and technology, with six stunning works on display until Jan 14, 2024.

In addition, families can appreciate traditional Chinese history, art and culture from a new perspective at the incredible Hong Kong Palace Museum. The harbourfront institution is a great place for families to explore local culture through fascinating year-round exhibitions and multimedia installations and also join hands-on creative workshops.

Travellers can enjoy sweet family time at family-friendly hotels such as Regala Skycity Hotel and The Fullerton Ocean Park Hotel Hong Kong.

Located in Skycity, Hong Kong International Airport, Regala Skycity Hotel boasts a number of colourful themed family suites in which kids can live out their prince and princess fantasies in the princess castle suite or feel the speed in the car racing suite.

Meanwhile, at The Fullerton Ocean Park Hotel Hong Kong is overloaded with cuteness surprises with a Baby Shark Adventure. Running until Nov 30, the experience includes a thematic guestroom and a range of experiences that revolve around the popular children’s song and TV show, Baby Shark.

— BERNAMA

Omico Will Precisely Match Patients to George Clinical Oncology Trials

SYDNEY, July 28 (Bernama-GLOBE NEWSWIRE) — George Clinical recognises and applauds its collaborative partner Omico, with whom it is aligned in a common goal to revolutionize oncology clinical trial access for patients and improve the efficiency of study enrollment, on the launch of their landmark program PrOSPeCT–a program that brings precision oncology trials to the Australian community by linking genomic technology to trials of new therapeutic products.

Omico is an Australian government-backed national network of leading researchers, clinicians and industry partners, including George Clinical, that are using precision medicine to unlock new potential in Australian research and turn the tide on cancer. With fast-tracked molecular screening, biomarker-led trial set up and patient enrolment across the entire nation, Omico is accelerating access to next-generation treatments and preventive strategies improving outcomes for all Australians affected by cancer.  

“Omico provides a faster, better way to perform cancer molecular screening, enroll patients and set up biomarker-led clinical trials thereby offering George Clinical, our sponsor partners, sites, and patients, the ability to match genetically eligible patients to cutting edge oncology clinical trials being conducted in Australia in a non-traditional, more efficient and direct model,” said Susan Cole, global head therapeutic strategy, oncology for George Clinical.

Through the PrOSPeCT initiative, Omico is further expanding its reach by opening up new treatment paths across Australia for people with difficult-to-treat cancers including those with ovarian cancers, pancreatic cancers, sarcomas, and advanced and metastatic cancers. PrOSPeCT has three main aims: to screen a magnitude of patients that is beneficial to the Australian public and the economy with 23,000 patients to access free, cutting edge genomic screening; to match patients to precision medicines in clinical trials that are being conducted across Australia; and to create a database of real-world data that will be useful in the future for further research.

”Omico is committed to supporting the Australian life sciences industry. It is through organizations like George Clinical that we support more clinical trials in Australia, creating new jobs, while bringing hope to our patients battling cancer”, says Professor David Thomas, oncologist, founder and CEO of Omico.

George Clinical’s success with oncology trials has been driven by scientific expertise and operational excellence. The synergy between the two organizations is no better demonstrated than the current collaboration undertaking early phase molecular screening dependent trials in Australia that require the ability to combine the targeted identification of patients through the use of the Omico’s PrOSPeCT initiative to accelerate access to precision oncology, and George Clinical’s focus on the scientific objective leading to success through maximizing site selection, recruitment, and overall trial efficiencies for the best result possible.

About George Clinical
George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With over 20 years of experience and more than 500 people managing over 39 geographical locations throughout the Asia-Pacific region, USA, and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration and post-marketing trials.

Matthew Reabold
George Clinical
760-645-0496
mreabold@georgeclinical.com

SOURCE: George Clinical

http://mrem.bernama.com/viewsm.php?idm=46690

VIENNA, July 28 (Bernama-BUSINESS WIRE) — The third instalment of the Animalis Edition at the 2023 – 2024 World Branding Awards welcomed pet and animal brands from around the world, celebrating their achievements as National, Regional, and Global Winners.

Held at the prestigious Hofburg Palace in Vienna, the awards ceremony was hosted by Howard Nightingall and welcomed winners across various categories, such as pet food, retail, wellness, aquatic products, and more.

“The Animalis Edition of the Awards are an acknowledgement to the tireless effort of the teams that build and maintain their brand presence in an ever changing market. As winners, these brands have established strong brand recall, top-of-mind awareness, and trust among their consumers.” said Richard Rowles, Chairman of the World Branding Forum.

Over 100,000 consumers participated in a global online survey and nominated more than 1,500 brands. Of these, only 100 of the best brands from 30 countries were named as winners.

Buddy Brands, Coo & Riku, Dymax, FRONTLINE, Hikari, Kaniva, and Taiyo were amongst the brands announced as winners. To win the World Branding Awards is no easy accolade, and cements their position as the top in their industry.

Winners from Malaysia include PowerCat, Catzonia, Aquaria KLCC, Aquanice, BACK2NATURE, Cindy’s Recipe, Royal Canin, and MSIG. Other National tier winners include Coo & Riku (Japan), DeliBest (Switzerland), Global Pet Foods (Canada), Halti (United Kingdom), Heads Up For Tails (India), Kelly & Co’s (Thailand), NurturePro (Singapore), TopBreed (The Philippines), and VanCat (Turkey).

As the 2023 – 2024 World Branding Awards Animalis Edition draws to a close, the eagerly anticipated Global Edition of the World Branding Awards will return to the stage in November in Kensington Palace, London.

For more information, visit awards.brandingforum.org.

ABOUT WORLD BRANDING AWARDS

The World Branding Awards is the premier awards of the World Branding Forum, a registered non-profit organisation. The awards recognise the achievements of some of the world’s best brands.

SOCIAL MEDIA

Facebook:https://www.facebook.com/worldbrandingforum/

Twitter:https://twitter.com/WorldBranding

Instagram:https://www.instagram.com/worldbranding/

LinkedIn:https://linkedin.com/company/world-branding-forum

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20230727486642/en/

Contact

editorial@brandingforum.org

Source : World Branding Awards

–BERNAMA

KUALA LUMPUR, July 26 (Bernama) — Clinical Research Malaysia (CRM) inked an education scholarship agreement with the Ministry of Health (MOH) and National Pharmaceutical Regulatory Agency (NPRA) earlier today at CRM headquarters. Under the agreement, CRM will be sponsoring two NPRA officers to pursue their Master’s program in Clinical Pharmacology at King’s College London.

The initiative is aligned with CRM’s Phase 1 Realisation Project (P1RP) 2.0, which focuses on further enhancing Malaysia’s capabilities on early phase/first-in-human trials. The project is an extension of the initial P1RP program launched in 2016 in which three NPRA officers and a Medical Oncologist from Sarawak General Hospital were sponsored for postgraduate studies and fellowship attachment respectively, at renowned global institutions, to build their expertise in early phase trials. Investment in human capital development is a continuous effort taken by CRM, an organization wholly-owned by the MOH, to ensure the country’s readiness for safe and high-quality conduct of clinical trials.

Representing the organisations at the signing ceremony were Deputy Secretary-General Finance of MOH, Dato’ Sri Norazman Ayob, Chief Executive Officer of CRM, Dr. Akhmal Yusof as well as NPRA officers Siti Norhayani Ismail and Fatin Diyana Fauzi. The sponsorship agreement was witnessed by YB Dr. Zaliha Mustafa, the Minister of Health and Rosilawati Ahmad, NPRA Director.

During the same program, YB Dr Zaliha also launched the Malaysia Decentralised Clinical Trial (DCT) Guidance Document. This guidance document is a first in Malaysia and will be an important step in aligning to the global trends of clinical trials where patient-centricity becomes more important, as well as adopting new and innovative clinical trial designs. The document was developed by clinical research stakeholders within the country and endorsed by the National Committee for Clinical Research.

About CRM
Established by Malaysian Ministry of Health in 2012, Clinical Research Malaysia is a Global Trusted Research Management Organisation guided by principles of HUMANITY, STABILITY & SUSTAINABILITY in providing global clinical trial solutions. CRM enables Speed, Reliability & Quality delivery of Sponsored Clinical Trials through innate understanding of the local clinical research landscape with the international standards of operations. These coupled with fundamental backing of the government ministries provides the organisation an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high-skilled job opportunities.

SOURCE: Clinical Research Malaysia (CRM)

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Siti Khadijah Sakaria 
Tel: + 6017 696 3596 | +603-7931 5566 (ext. 119)   
Email: sitikhadijah@clinicalresearch.my 

–BERNAMA

KUALA LUMPUR, July 25 (Bernama) — Curia, a contract research, development and manufacturing organisation, and Touchlight, a company pioneering enzymatic DNA production, announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight’s doggybone DNA (dbDNA).

The arrangement expands Curia’s messenger ribonucleic acid (mRNA) manufacturing offerings with an additional differentiated source of DNA raw material that is immediately available to be accessed by Curia customers, while Touchlight will directly manufacture dbDNA on behalf of Curia’s customers.

“Curia remains committed to strengthening our biologics offerings and end-to-end mRNA manufacturing capabilities.

“With the addition of enzymatic DNA through our partnership with Touchlight, our customers will have a critical advantage in terms of scalability and speed to market,” said Curia President of R&D, Christopher Conway in a statement.

Meanwhile, Touchlight Chief Executive Officer, Karen Fallen said: “We are delighted to work with Curia in order to further expand access to dbDNA as a critical starting material.

“Curia is building a comprehensive mRNA solution, and this arrangement enables both companies to extend their offering to a wider audience.”

Touchlight’s dbDNA is a linear, double-stranded, covalently-closed DNA vector. DNA serves as the template for making mRNA therapies, and via a simple enzymatic process called in vitro transcription, genetic information is copied from DNA to mRNA.

This mRNA is then able to teach the cells to make precise proteins that are used to treat or prevent diseases. Touchlight’s enzymatic DNA is produced with a cell-free enzymatic process that offers unmatched benefits in speed, quality and capacity when compared to traditional plasmid DNA production.

— BERNAMA